The global Radiotherapy Market is advancing on a steady and meaningful growth trajectory, driven by the continued rise in global cancer incidence, ongoing technological innovation in radiation delivery, and expanding investment in oncology infrastructure across developed and emerging markets. Kings Research projects the market to grow from USD 8.07 billion in 2025 to USD 11.80 billion by 2032, at a CAGR of 5.48%, reflecting the enduring importance of radiation therapy in comprehensive cancer care.
Key Market Statistics at a Glance
Market Value (2025): USD 8.07 Billion
Projected Value (2032): USD 11.80 Billion
CAGR (2025–2032): 5.48%
Technology Types: External Beam Radiotherapy, Brachytherapy, Proton Therapy, Radiopharmaceuticals
End Users: Hospitals, Freestanding Radiotherapy Centers, Cancer Research Institutes
Forecast Period: 2025–2032
Market Overview
Radiotherapy is one of the three primary modalities of cancer treatment — alongside surgery and systemic therapy — and is used in the management of approximately 50% of all cancer patients at some point during their care. The modality uses ionizing radiation — generated by linear accelerators, radioactive isotopes, or proton/heavy-ion accelerators — to damage cancer cell DNA, impairing their ability to divide and eventually causing cell death. Radiotherapy is applied both with curative intent and as a palliative tool to reduce tumor burden, relieve pain, and preserve organ function in patients with advanced disease. Advances in imaging, planning technology, and delivery hardware are continuously expanding the precision and clinical utility of radiotherapy.
Key Growth Drivers
- Rising global cancer burden with WHO projecting millions of new diagnoses annually across aging populations
- Expansion of radiotherapy infrastructure in Africa, Asia, and Latin America addressing significant unmet need
- Technological advances including MR-guided radiotherapy and proton therapy expanding clinical indications
- Integration of AI into treatment planning and quality assurance workflows improving efficiency and accessibility
- Growing evidence supporting hypofractionation enabling shorter treatment courses with equivalent outcomes
- Radiopharmaceutical therapy expansion creating new targeted radiation modalities beyond conventional RT
Technology Segmentation
External beam radiotherapy (EBRT) using linear accelerators (linacs) remains the dominant technology segment, accounting for the substantial majority of radiotherapy procedures globally. Within EBRT, techniques including IMRT, VMAT, stereotactic radiosurgery (SRS), and stereotactic body radiotherapy (SBRT) represent the current clinical standard, offering increasing precision and efficiency. Brachytherapy — the placement of radioactive sources directly within or adjacent to tumors — retains important clinical roles in prostate, cervical, and breast cancer treatment, offering highly localized dose delivery. Proton therapy is the premium segment, growing steadily as evidence accumulates and facility counts increase worldwide. Targeted radionuclide therapy — including lutetium-177-based radiopharmaceuticals — is one of the fastest-growing subsegments, representing a convergence of nuclear medicine and oncology with compelling clinical results in neuroendocrine tumors and prostate cancer.
Regional Analysis
North America leads the global radiotherapy market, driven by high cancer incidence rates, advanced treatment centers, comprehensive reimbursement frameworks, and ongoing equipment modernization programs. The United States accounts for the largest share of global radiotherapy system installations and represents the primary market for premium technologies such as proton therapy and MR-Linac systems. Europe is the second-largest market, with national health systems actively investing in linac fleet upgrades and innovative technology adoption. Germany, the United Kingdom, France, and the Netherlands are among the leading European radiotherapy markets. Asia-Pacific is the fastest-growing regional market, with China undertaking a massive expansion of radiotherapy capacity, India significantly increasing linac installations, and Japan investing in advanced proton therapy facilities.
Competitive Landscape
The radiotherapy equipment market is dominated by three major companies: Varian Medical Systems (now part of Siemens Healthineers), Elekta, and Accuray, which collectively supply the vast majority of linear accelerators globally. These companies compete on system performance, software ecosystem, service infrastructure, and innovation roadmap. Specialized proton therapy system providers including Varian (ProBeam), Hitachi, Sumitomo Heavy Industries, and Mevion serve the smaller but growing proton therapy market. Treatment planning software vendors including RaySearch Laboratories, Brainlab, and the software divisions of the linac manufacturers compete on automation, AI integration, and adaptive radiotherapy capabilities. The radiopharmaceutical segment is served by a distinct set of companies including Novartis (Lutathera), POINT Biopharma, and ITM Isotope Technologies.
Emerging Trends
- MR-Linac systems enabling real-time adaptive radiotherapy becoming established in major cancer centers
- Flash radiotherapy delivering ultra-high dose rates showing preclinical promise for normal tissue sparing
- AI-driven fully automated treatment planning reducing physics workload and accelerating time-to-treatment
- Targeted radionuclide therapy expanding as a systemic radiation modality for metastatic cancers
- Shorter hypofractionation regimens reducing patient visits and expanding radiotherapy access
- Global radiotherapy access initiatives addressing the significant equipment gap in low-income countries
Conclusion
Radiotherapy remains an irreplaceable pillar of cancer care, with its clinical role continuously strengthened by technological innovation that improves precision, expands indications, and reduces treatment burden. With the global market projected to reach USD 11.80 billion by 2032, the sector offers durable growth opportunities for equipment manufacturers, software developers, clinical service providers, and healthcare investors. The dual imperatives of improving treatment outcomes in high-resource settings and expanding access in underserved markets will continue to drive innovation and investment in radiation oncology for the foreseeable future.
Full Report: Radiotherapy Market Report
Publisher: Kings Research | Category: Technology & Healthcare Market Research
About Kings Research
Kings Research is a premier market research and consulting organization delivering in-depth, data-driven intelligence across technology, healthcare, energy, industrial, and consumer sectors. The firm’s rigorous research methodology combines primary interviews, secondary data analysis, and proprietary modeling to produce actionable insights that empower businesses, investors, and policymakers to make confident strategic decisions.
